0
Your cart

Your cart is empty

Books > Medicine > Other branches of medicine > Pharmacology

Buy Now

Cancer Therapeutics - Experimental and Clinical Agents (Paperback, Softcover reprint of the original 1st ed. 1997) Loot Price: R5,510
Discovery Miles 55 100
Cancer Therapeutics - Experimental and Clinical Agents (Paperback, Softcover reprint of the original 1st ed. 1997): Beverly A....

Cancer Therapeutics - Experimental and Clinical Agents (Paperback, Softcover reprint of the original 1st ed. 1997)

Beverly A. Teicher

Series: Cancer Drug Discovery and Development

 (sign in to rate)
Loot Price R5,510 Discovery Miles 55 100 | Repayment Terms: R516 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.

General

Imprint: HumanaPress
Country of origin: United States
Series: Cancer Drug Discovery and Development
Release date: November 2010
First published: 1997
Editors: Beverly A. Teicher
Dimensions: 254 x 178 x 23mm (L x W x T)
Format: Paperback
Pages: 451
Edition: Softcover reprint of the original 1st ed. 1997
ISBN-13: 978-1-61737-046-5
Categories: Books > Medicine > Other branches of medicine > Pharmacology > General
LSN: 1-61737-046-0
Barcode: 9781617370465

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners